Biolex Therapeutics
Latest round
- Series D
Last raised
- Oct 2008
Total raised
- $133M
Investors
- 18
About Biolex Therapeutics
Biolex Therapeutics, Inc. is a biopharmaceutical company based in North Carolina, US. It offers Locteron, a controlled-release interferon alfa for the treatment of hepatitis C; BLX-155, a thrombolytic or clot buster to dissolve blood clots; and BLX-301, an antibody for the treatment of B-cell lymphoma.
Who invested in Biolex Therapeutics
18 investors across 4 rounds
See all investors in Biolex Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biolex Therapeutics
Who invested in Biolex Therapeutics?
Biolex Therapeutics has 18 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biolex Therapeutics raised?
Biolex Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Biolex Therapeutics last raise money?
Biolex Therapeutics's most recent round on record is a Series D, in Oct 2008.
What does Biolex Therapeutics do?
Biolex Therapeutics is a biotechnology company.
Where is Biolex Therapeutics headquartered?
Biolex Therapeutics is headquartered in US.
Which VCs invest in companies like Biolex Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Biolex Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Biolex Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.